 EMERYVILLE, Calif.--BUSINESS WIRE--Adamas Pharmaceuticals, Inc. Nasdaq: ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of an article entitled Amantadine ER Gocovri significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinsons disease in the peer-reviewed journal Frontiers in Neurology. GOCOVRI amantadine extend 